News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

October 9, 2020 Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
October 5, 2020 Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
October 3, 2020 Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
September 24, 2020 Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
September 21, 2020 Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
September 15, 2020 Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
September 2, 2020 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
July 31, 2020 Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
July 7, 2020 Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
July 2, 2020 Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)